Global Antibody Production Market – North America is expected to account for higher market share of more than 55% driven by number of biotechnology and pharmaceutical firm: Global Market Analysis 2013 – 2017 and Forecast 2018 – 2024

Global Antibody Production Market – North America is expected to account for higher market share of more than 55% driven by number of biotechnology and pharmaceutical firm: Global Market Analysis 2013 – 2017 and Forecast 2018 – 2024

Market Scenario

Global Antibody Production Market is expected to grow at a CAGR of 14.2% to reach US$ 16.32 billion in 2024. The growth is coupled with an increasing need for protein curatives and rising widespread presence of infectious disease. The other factors propelling the growth of the Global Antibody Production Market are the patent cessation of successful monoclonal antibodies, raised R&D disbursement of biotechnology and pharmaceutical companies, rising acceptance of targeted immunotherapy and therapeutic antibodies by governing authorities. The increasing focus of biopharmaceutical & biotechnology companies to produce antibody therapeutics is a major factor driving the growth. These therapeutics are highly effective in the treatment of rheumatoid arthritis, cancer, and other chronic diseases. Thus, the production of therapeutic antibodies is increasing, which is expected to drive the growth of the Global Antibody Production Market during the forecast period. North America had the highest market share in 2017. The Global Antibody Production Market is driven by the factor including the presence of many large biotechnology and biopharmaceutical firms in this region. In addition, the highly developed healthcare & research infrastructure and increased focus on drug discovery in North America have fuelled the regional Global Antibody Production Market growth. The Asia Pacific is expected to exhibit the highest growth during the forecast period, owing to untapped opportunities in this region. There are many biopharmaceutical and clinical research organizations companies, which are targeting Asian countries, such as China & India for drug discovery and development. The presence of less stringent regulations for antibodies development & production, vast genome pool, and developing healthcare infrastructure in this region are some of the major factors contributing to the growth of the sector in this region. In 2017, the monoclonal antibody segment was the highest revenue-generating segment of the market, due to increasing investment in monoclonal antibody research and many antibody-based product launches. Thus, the growing adoption of these products is expected to be the key factor driving the Global Antibody Production Market. Global Antibody Production Market

Global Antibody Production Market Segmentation

•Global Antibody Production Market, By Type

o Polyclonal antibody o Monoclonal antibody  Murine  Chimeric  Humanized

• Global Antibody Production Market, By Process

o Upstream processing  Bioreactors • Largescale bioreactors • Single-use bioreactors  Consumables • Media • Buffers and reagents o Downstream processing  Chromatography systems  Chromatography resins o Filtration  Filtration systems  Filtration consumables and accessories

• Global Antibody Production Market, By End User

o Pharmaceutical and biotechnology companies o Research laboratories o Others The above data will be provided for following regions/countries from 2013-2024 (USD Million) • North America o U.S. o Canada • Europe o Germany o UK o France o Spain o Italy • Asia Pacific o China o India o Japan o Australia • Latin America o Argentina o Brazil o Mexico • Middle East and Africa o South Africa o Saudi Arabia What information is covered in report? • Actual market numbers from 2013-2017, estimates and forecasts from 2018 to 2024 • Detailed market segmentation and market share analysis of each segment • Impact analysis of various drivers and trends • Market segmentation and landscape • Competitive landscape, 2017 Global Dental Sterilization Devices Market 

Table of Contents

Global Antibody Production Market

Chapter 1 Research Methodology 1.1. Research Methodology 1.2. Market definition 1.3. Assumptions and Acronyms Used 1.4. Data Sources 1.4.1. Secondary 1.4.1.1. Paid 1.4.1.2. Unpaid 1.4.2. Primary Chapter 2 Executive Summary 2.1. Global Antibody Production Market overview 2.1.1. By Type 2.1.2. By Process 2.1.3. By End User Chapter 3 Global Antibody Production Market Industry Insights 3.1. Market segmentation and scope of study 3.2. Market Drivers and their impact analysis 3.2.1. Market Drivers 3.2.1.1. Increasing incidences of cancer 3.2.1.2. Rapid technological advancements 3.2.2. Market Restrains 3.2.2.1. Unawareness for the diagnosis of chronic diseases 3.3. Market share analysis 3.3.1. By Type 3.3.2. By Process 3.3.3. By End User 3.4. Competitive analysis 3.4.1. Key strategic initiatives 3.4.2. Regional presence 3.4.3. Product overview 3.5. Porter’s analysis 3.6. PESTEL analysis Chapter 4 Antibody Production Market, By Types 4.1. Key segment trends 4.2. Polyclonal antibody 4.2.1. Market size, by region, 2013 - 2024 4.3. Monoclonal antibody 4.3.1. Market size, by region, 2013 – 2024 4.4. Murine 4.4.1. Market size, by region, 2013 – 2024 4.5. Chimeric 4.5.1. Market size, by region, 2013 – 2024 4.6. Humanized 4.6.1. Market size, by region, 2013 – 2024 4.6.2. Key Trends in Global Antibody Production Market Chapter 5 Antibody Production Market, By Process 5.1. Key segment trends 5.2. Upstream processing 5.2.1. Market size, by region, 2013 - 2024 5.3. Bioreactors 5.3.1. Market size, by region, 2013 – 2024 5.4. Largescale bioreactors 5.4.1. Market size, by region, 2013 – 2024 5.5. Single-use bioreactors 5.5.1. Market size, by region, 2013 – 2024 5.6. Consumables 5.6.1. Market size, by region, 2013 - 2024 5.7. Media 5.7.1. Market size, by region, 2013 – 2024 5.8. Buffers and reagents 5.8.1. Market size, by region, 2013 – 2024 5.9. Downstream processing 5.9.1. Market size, by region, 2013 – 2024 5.10. Chromatography systems 5.10.1. Market size, by region, 2013 - 2024 5.11. Chromatography resins 5.11.1. Market size, by region, 2013 – 2024 5.12. Filtration 5.12.1. Market size, by region, 2013 – 2024 5.13. Filtration systems 5.13.1. Market size, by region, 2013 – 2024 5.14. Filtration consumables and accessories 5.14.1. Market size, by region, 2013 – 2024 Chapter 6 Antibody Production Market, By End-User 6.1. Key segment trends 6.2. Pharmaceutical and biotechnology companies 6.2.1. Market size, by region, 2013 - 2024 6.3. Research laboratories 6.3.1. Market size, by region, 2013 – 2024 6.4. Others 6.4.1. Market size, by region, 2013 – 2024 Chapter 7 Antibody Production Market, By Region 7.1. Key regional trends 7.2. North America 7.2.1. Market size, by country, 2013 – 2024 7.2.2. Market size, by type, 2013 – 2024 7.2.3. Market size, by process, 2013 – 2024 7.2.4. Market size, by end-user, 2013 – 2024 7.2.5. U.S. 7.2.5.1. Market size, by type, 2013 – 2024 7.2.5.2. Market size, by process, 2013 – 2024 7.2.5.3. Market size, by end-user, 2013 – 2024 7.2.6. Canada 7.2.6.1. Market size, by type, 2013 – 2024 7.2.6.2. Market size, by process, 2013 – 2024 7.2.6.3. Market size, by end-user, 2013 – 2024 7.3. Europe 7.3.1. Market size, by country, 2013 – 2024 7.3.2. Market size, by type, 2013 – 2024 7.3.3. Market size, by process, 2013 – 2024 7.3.4. Market size, by end-user, 2013 – 2024 7.3.5. Germany 7.3.5.1. Market size, by type, 2013 – 2024 7.3.5.2. Market size, by process, 2013 – 2024 7.3.5.3. Market size, by end-user, 2013 – 2024 7.3.6. UK 7.3.6.1. Market size, by type, 2013 – 2024 7.3.6.2. Market size, by process, 2013 – 2024 7.3.6.3. Market size, by end-user, 2013 – 2024 7.3.7. France 7.3.7.1. Market size, by type, 2013 – 2024 7.3.7.2. Market size, by process, 2013 – 2024 7.3.7.3. Market size, by end-user, 2013 – 2024 7.3.8. Spain 7.3.8.1. Market size, by type, 2013 – 2024 7.3.8.2. Market size, by process, 2013 – 2024 7.3.8.3. Market size, by end-user, 2013 – 2024 7.3.9. Italy 7.3.9.1. Market size, by type, 2013 – 2024 7.3.9.2. Market size, by process, 2013 – 2024 7.3.9.3. Market size, by end-user, 2013 – 2024 7.4. Asia Pacific 7.4.1. Market size, by country, 2013 – 2024 7.4.2. Market size, by type, 2013 – 2024 7.4.3. Market size, by process, 2013 – 2024 7.4.4. Market size, by end-user, 2013 – 2024 7.4.5. India 7.4.5.1. Market size, by type, 2013 – 2024 7.4.5.2. Market size, by process, 2013 – 2024 7.4.5.3. Market size, by end-user, 2013 – 2024 7.4.6. China 7.4.6.1. Market size, by type, 2013 – 2024 7.4.6.2. Market size, by process, 2013 – 2024 7.4.6.3. Market size, by end-user, 2013 – 2024 7.4.7. Japan 7.4.7.1. Market size, by type, 2013 – 2024 7.4.7.2. Market size, by process, 2013 – 2024 7.4.7.3. Market size, by end-user, 2013 – 2024 7.4.8. Australia 7.4.8.1. Market size, by type, 2013 – 2024 7.4.8.2. Market size, by process, 2013 – 2024 7.4.8.3. Market size, by end-user, 2013 – 2024 7.5. Latin America 7.5.1. Market size, by country, 2013 – 2024 7.5.2. Market size, by type, 2013 – 2024 7.5.3. Market size, by process, 2013 – 2024 7.5.4. Market size, by end-user, 2013 – 2024 7.5.5. Argentina 7.5.5.1. Market size, by type, 2013 – 2024 7.5.5.2. Market size, by process, 2013 – 2024 7.5.5.3. Market size, by end-user, 2013 – 2024 7.5.6. Brazil 7.5.6.1. Market size, by type, 2013 – 2024 7.5.6.2. Market size, by process, 2013 – 2024 7.5.6.3. Market size, by end-user, 2013 – 2024 7.5.7. Mexico 7.5.7.1. Market size, by type, 2013 – 2024 7.5.7.2. Market size, by process, 2013 – 2024 7.5.7.3. Market size, by end-user, 2013 – 2024 7.6. Middle East and Africa 7.6.1. Market size, by country, 2013 – 2024 7.6.2. Market size, by type, 2013 – 2024 7.6.3. Market size, by process, 2013 – 2024 7.6.4. Market size, by end-user, 2013 – 2024 7.6.5. South Africa 7.6.5.1. Market size, by type, 2013 – 2024 7.6.5.2. Market size, by process, 2013 – 2024 7.6.5.3. Market size, by end-user, 2013 – 2024 7.6.6. Saudi Arabia 7.6.6.1. Market size, by type, 2013 – 2024 7.6.6.2. Market size, by process, 2013 – 2024 7.6.6.3. Market size, by end-user, 2013 – 2024 Chapter 8 Consolidations 8.1. Mergers and Acquisitions 8.2. Partnership, Joint Ventures and Strategic Alliances/Sales Agreements 8.3. Patent Analysis 8.4. Key players 8.4.1. GE Healthcare 8.4.1.1. Company overview 8.4.1.2. Key financials 8.4.1.3. Product landscape 8.4.1.4. Strategic initiatives 8.4.1.5. SWOT analysis 8.4.2. Thermo Fisher Scientific, Inc. 8.4.2.1. Company overview 8.4.2.2. Key financials 8.4.2.3. Product landscape 8.4.2.4. Strategic initiatives 8.4.2.5. SWOT analysis 8.4.3. Sartorius AG 8.4.3.1. Company overview 8.4.3.2. Key financials 8.4.3.3. Product landscape 8.4.3.4. Strategic initiatives 8.4.3.5. SWOT analysis 8.4.4. Merck KGaA 8.4.4.1. Company overview 8.4.4.2. Key financials 8.4.4.3. Product landscape 8.4.4.4. Strategic initiatives 8.4.4.5. SWOT analysis 8.4.5. Argon Medical Devices 8.4.5.1. Company overview 8.4.5.2. Key financials 8.4.5.3. Product landscape 8.4.5.4. Strategic initiatives 8.4.5.5. SWOT analysis 8.4.6. Pall Corp. 8.4.6.1. Company overview 8.4.6.2. Key financials 8.4.6.3. Product landscape 8.4.6.4. Strategic initiatives 8.4.6.5. SWOT analysis 8.4.7. Cardinal Health, Inc. 8.4.7.1. Company overview 8.4.7.2. Key financials 8.4.7.3. Product landscape 8.4.7.4. Strategic initiatives 8.4.7.5. SWOT analysis 8.4.8. Olympus Corporation 8.4.8.1. Company overview 8.4.8.2. Key financials 8.4.8.3. Product landscape 8.4.8.4. Strategic initiatives 8.4.8.5. SWOT analysis 8.4.9. Boston Scientific Corporation 8.4.9.1. Company overview 8.4.9.2. Key financials 8.4.9.3. Product landscape 8.4.9.4. Strategic initiatives 8.4.9.5. SWOT analysis 8.4.10. Eppendorf AG 8.4.10.1. Company overview 8.4.10.2. Key financials 8.4.10.3. Product landscape 8.4.10.4. Strategic initiatives 8.4.10.5. SWOT analysis 8.4.11. INRAD, Inc. 8.4.11.1. Company overview 8.4.11.2. Key financials 8.4.11.3. Product landscape 8.4.11.4. Strategic initiatives 8.4.11.5. SWOT analysis 8.4.12. Medtronic plc 8.4.12.1. Company overview 8.4.12.2. Key financials 8.4.12.3. Product landscape 8.4.12.4. Strategic initiatives 8.4.12.5. SWOT analysis 8.4.13. Leica Biosystems 8.4.13.1. Company overview 8.4.13.2. Key financials 8.4.13.3. Product landscape 8.4.13.4. Strategic initiatives 8.4.13.5. SWOT analysis 8.4.14. Hologic, Inc. 8.4.14.1. Company overview 8.4.14.2. Key financials 8.4.14.3. Product landscape 8.4.14.4. Strategic initiatives 8.4.14.5. SWOT analysis 8.4.15. Cellab GmbH 8.4.15.1. Company overview 8.4.15.2. Key financials 8.4.15.3. Product landscape 8.4.15.4. Strategic initiatives 8.4.15.5. SWOT analysis 8.4.16. Veran Medical Technologies 8.4.16.1. Company overview 8.4.16.2. Key financials 8.4.16.3. Product landscape 8.4.16.4. Strategic initiatives 8.4.16.5. SWOT analysis 8.4.17. Boston Scientific Corporation 8.4.17.1. Company overview 8.4.17.2. Key financials 8.4.17.3. Product landscape 8.4.17.4. Strategic initiatives 8.4.17.5. SWOT analysis 8.4.18. MDxHealth 8.4.18.1. Company overview 8.4.18.2. Key financials 8.4.18.3. Product landscape 8.4.18.4. Strategic initiatives 8.4.18.5. SWOT analysis 8.4.19. Mauna Kea Technologies 8.4.19.1. Company overview 8.4.19.2. Key financials 8.4.19.3. Product landscape 8.4.19.4. Strategic initiatives 8.4.19.5. SWOT analysis 8.4.20. Argon Medical Devices, Inc 8.4.20.1. Company overview 8.4.20.2. Key financials 8.4.20.3. Product landscape 8.4.20.4. Strategic initiatives 8.4.20.5. SWOT analysis 8.4.21. Intact Medical Corp. 8.4.21.1. Company overview 8.4.21.2. Key financials 8.4.21.3. Product landscape 8.4.21.4. Strategic initiatives 8.4.21.5. SWOT analysis 8.4.22. Carefusion Corporation 8.4.22.1. Company overview 8.4.22.2. Key financials 8.4.22.3. Product landscape 8.4.22.4. Strategic initiatives 8.4.22.5. SWOT analysis 8.4.23. Devicor Medical Products, Inc. 8.4.23.1. Company overview 8.4.23.2. Key financials 8.4.23.3. Product landscape 8.4.23.4. Strategic initiatives 8.4.23.5. SWOT analysis 8.4.24. INTEGRA Biosciences AG 8.4.24.1. Company overview 8.4.24.2. Key financials 8.4.24.3. Product landscape 8.4.24.4. Strategic initiatives 8.4.24.5. SWOT analysis 8.4.25. FiberCell Systems Inc. 8.4.25.1. Company overview 8.4.25.2. Key financials 8.4.25.3. Product landscape 8.4.25.4. Strategic initiatives 8.4.25.5. SWOT analysis

Inquiry Before Buying

Request Sample

About This Report

Report ID 10975
Published Date
Contact Us
Call Now